Dr. Lin is founder, CEO and chairman of AbGenomics. To better position the company, Dr. Lin established twin headquarters in both Taipei and San Francisco Bay Area where he and his team can efficiently collaborate with world top talents and key opinion leaders in the medical fields. He is the key inventor of more than a dozen worldwide patents. Under his leadership and well established collaborative culture, the company discovered several promising therapeutic candidates successfully.Prior to joining AbGenomics, Dr. Lin was founding Professor and Director of Graduate Institute of Immunology, College of Medicine, National Taiwan University. Dr. Lin also served as an Associate Editor for Journal of Biomedical Science and a member of the Editorial Board for Int. Immunopharmacology . He received his Diplom, Summa Cum Laude, and Doctor (in Immunology), Magna Cum Laude, degrees from the University of Tübingen in Germany. He has conducted his research works in 3 world renowned institutions: Max Planck Institute for Immunogenetics in Germany, Basel Institute for Immunology in Switzerland, and Immunobiology Division at Howard Hughes Medical Institute at Yale University. In his previous academic research journey he has supervised several physicians from different departments to conduct translational researches and published more than 50 refereed papers.

Immunopharmacology, Immunogenetics